SynthesisWorld journal of gastroenterology2019
Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature.
Synthesis in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Liver support systems for adults with acute liver failure.The Cochrane database of systematic reviews · 2026Pooled it
- Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis.Critical care explorations · 2025Pooled it
- Observational
- Article
- Diagnostic Value of Correlation Between Canine Chronic Enteropathy Clinical Activity Index (CCECAI) and Selected Hematological and Immunological Biomarkers in Dogs with Chronic Enteropathy: A Systematic Meta-Analysis.Veterinary sciences · 2026Article
- Enhancing Long-Term Survival and Self-Renewal of Primary Hepatocytes via Rapid Spheroid Formation Using Rocker System through Co-Culturing with HUVEC Over-Expressing RSPO1.Tissue engineering and regenerative medicine · 2025Article
- Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.Life (Basel, Switzerland) · 2025Review
- Implantable 3D printed hydrogels with intrinsic channels for liver tissue engineering.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Liver organoids cocultured on decellularized native liver scaffolds as a bridging therapy improves survival from liver failure in rabbits.In vitro cellular & developmental biology. Animal · 2023Article
- Toward better drug development: Three-dimensional bioprinting in toxicological research.International journal of bioprinting · 2023Review
- Review
- Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions.Journal of clinical and translational hepatology · 2022Review
- Acute kidney injury and hepatorenal syndrome in cirrhosis.World journal of gastroenterology · 2021Review
- A Perfusion Bioreactor for Longitudinal Monitoring of Bioengineered Liver Constructs.Nanomaterials (Basel, Switzerland) · 2021Article
- Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis.Annals of intensive care · 2021Review
- Engineering liver microtissues for disease modeling and regenerative medicine.Advanced functional materials · 2020Article
- Options in extracorporeal support of multiple organ failure.Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020Review
- Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint.Annals of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute liver failure (ALF) has a high mortality varying from 80% to 85% with rapid progress in multi-organ system failure. Bioartificial liver (BAL) support systems have the potential to provide temporary support to bridge patients with ALF to liver transplantation or spontaneous recovery. In the past decades, several BAL support systems have been conducted in clinical trials. More recently, concerns have been raised on the renovation of high-quality cell sources and configuration of BAL support systems to provide more benefits to ALF models in preclinical experiments.
aimTo investigate the characteristics of studies about BAL support systems for ALF, and to evaluate their effects on mortality.
methodsEligible clinical trials and preclinical experiments on large animals were identified on Cochrane Library, PubMed, and EMbase up to March 6, 2019. Two reviewers independently extracted the necessary information, including key BAL indicators, survival and indicating outcomes, and adverse events during treatment. Descriptive analysis was used to identify the characteristics of the included studies, and a meta-analysis including only randomized controlled trial (RCT) studies was done to calculate the overall effect of BAL on mortality among humans and large animals, respectively.
resultsOf the 30 selected studies, 18 were clinical trials and 12 were preclinical experiments. The meta-analysis result suggested that BAL might reduce mortality in ALF in large animals, probably due to the recent improvement of BAL, including the type, cell source, cell mass, and bioreactor, but seemed ineffective for humans [BAL
conclusionBAL may reduce the mortality of ALF by bridging the gap between preclinical experiments and clinical trials. Clinical trials using improved BAL must be designed scientifically and conducted in the future to provide evidence for transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.